Allogeneic human umbilical cord blood for acute ischemic stroke: Phase I clinical trial
The IV hUCB was safe and well tolerated in AIS patients, and the preliminary efficacy results demonstrated its therapeutic potential, supporting the conduct of a randomized, placebo controlled, phase II clinical trial in future.
Authors
- Jonas C. Wang
- Raymond Y. Lo (ORCID: https://orcid.org/0000-0001-6510-1935)
- Jen-Hung Wang
- Shu‐Cin Chen
- Shinn‐Zong Lin (ORCID: https://orcid.org/0000-0002-4601-9933)
- Tong-Young Lee
- Y.-H. Luo (ORCID: https://orcid.org/0009-0007-9999-1826)
- Yu-Chin Su (ORCID: https://orcid.org/0000-0002-8510-8365)
- Yingjie Chen (ORCID: https://orcid.org/0000-0002-4059-7847)
- Chen-Yu Ko
Institutions
- National Yang Ming Chiao Tung University (TW)
- Tzu Chi University (TW)
- Tzu Chi Foundation (TW)
- National Dong Hwa University (TW)
- StemCyte (US)
- Hualien Tzu Chi Medical Center (TW)
- Stem Cell Technology (Taiwan) (TW)
Publication Details
- Journal
- Tzu Chi Medical Journal
- Published
- 2025-05-09
- DOI
- https://doi.org/10.4103/tcmj.tcmj_249_24
- Citations
- 1
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 1.35